Novocure's Optune Pax device received a CE Mark for locally advanced pancreatic cancer supported by significant overall survival improvements in the PANOVA-3 trial. This regulatory milestone expands the device's market reach and addresses the critical need for effective therapies in pancreatic cancer treatment.